Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Gut

Retrieve available abstracts of 188 articles:
HTML format



Single Articles


    June 2021
  1. HANSEN R, Meade S, Beattie RM, Auth MK, et al
    Adaptations to the current ECCO/ESPGHAN guidelines on the management of paediatric acute severe colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel.
    Gut. 2021;70:1044-1052.
    PubMed     Abstract available


    May 2021
  2. KENNEDY NA, Goodhand JR, Bewshea C, Nice R, et al
    Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.
    Gut. 2021;70:865-875.
    PubMed     Abstract available


    April 2021

  3. Correction: British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.
    Gut. 2021;70:1.
    PubMed    


  4. LEES CW, Irving PM, Beaugerie L
    COVID-19 and IBD drugs: should we change anything at the moment?
    Gut. 2021;70:632-634.
    PubMed    


  5. SIEGEL CA, Melmed GY, McGovern DP, Rai V, et al
    SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting.
    Gut. 2021;70:635-640.
    PubMed    


  6. UNGARO RC, Brenner EJ, Gearry RB, Kaplan GG, et al
    Effect of IBD medications on COVID-19 outcomes: results from an international registry.
    Gut. 2021;70:725-732.
    PubMed     Abstract available


    March 2021
  7. ASHTON JJ, Ennis S, Beattie RM
    Infliximab at diagnosis: moving towards personalisation in paediatric inflammatory bowel disease.
    Gut. 2021 Mar 15. pii: gutjnl-2021-324214. doi: 10.1136/gutjnl-2021-324214.
    PubMed    


    January 2021
  8. D'HAENS GR, van Deventer S
    25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future.
    Gut. 2021 Jan 11. pii: gutjnl-2019-320022. doi: 10.1136/gutjnl-2019-320022.
    PubMed     Abstract available


    December 2020
  9. LU TX, Dapas M, Lin E, Peters T, et al
    The influence of proton pump inhibitor therapy on the outcome of infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies.
    Gut. 2020 Dec 17. pii: gutjnl-2020-321609. doi: 10.1136/gutjnl-2020-321609.
    PubMed     Abstract available


  10. HE X, Gao J, Peng L, Hu T, et al
    Bacterial O-GlcNAcase genes abundance decreases in ulcerative colitis patients and its administration ameliorates colitis in mice.
    Gut. 2020 Dec 12. pii: gutjnl-2020-322468. doi: 10.1136/gutjnl-2020-322468.
    PubMed     Abstract available


  11. HAIFER C, Saikal A, Paramsothy R, Kaakoush NO, et al
    Response to faecal microbiota transplantation in ulcerative colitis is not sustained long term following induction therapy.
    Gut. 2020 Dec 10. pii: gutjnl-2020-323581. doi: 10.1136/gutjnl-2020-323581.
    PubMed    


  12. PAONE P, Cani PD
    Mucus barrier, mucins and gut microbiota: the expected slimy partners?
    Gut. 2020;69:2232-2243.
    PubMed     Abstract available


    November 2020
  13. DERKINDEREN P, Noble W, Neunlist M, Rolli-Derkinderen M, et al
    Upregulation of enteric alpha-synuclein as a possible link between inflammatory bowel disease and Parkinson's disease.
    Gut. 2020 Nov 17. pii: gutjnl-2020-323482. doi: 10.1136/gutjnl-2020-323482.
    PubMed    


  14. KHALOIAN S, Rath E, Hammoudi N, Gleisinger E, et al
    Mitochondrial impairment drives intestinal stem cell transition into dysfunctional Paneth cells predicting Crohn's disease recurrence.
    Gut. 2020;69:1939-1951.
    PubMed     Abstract available


    October 2020
  15. BLACKWELL J, Saxena S, Petersen I, Hotopf M, et al
    Depression in individuals who subsequently develop inflammatory bowel disease: a population-based nested case-control study.
    Gut. 2020 Oct 27. pii: gutjnl-2020-322308. doi: 10.1136/gutjnl-2020-322308.
    PubMed     Abstract available


  16. LEE HS, Lobbestael E, Vermeire S, Sabino J, et al
    Inflammatory bowel disease and Parkinson's disease: common pathophysiological links.
    Gut. 2020 Oct 16. pii: gutjnl-2020-322429. doi: 10.1136/gutjnl-2020-322429.
    PubMed     Abstract available


  17. KANIS SL, Modderman S, Escher JC, Erler N, et al
    Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life.
    Gut. 2020 Oct 12. pii: gutjnl-2019-319129. doi: 10.1136/gutjnl-2019-319129.
    PubMed     Abstract available


  18. ASCHENBRENNER D, Quaranta M, Banerjee S, Ilott N, et al
    Deconvolution of monocyte responses in inflammatory bowel disease reveals an IL-1 cytokine network that regulates IL-23 in genetic and acquired IL-10 resistance.
    Gut. 2020 Oct 9. pii: gutjnl-2020-321731. doi: 10.1136/gutjnl-2020-321731.
    PubMed     Abstract available


  19. DIN S, Kent A, Pollok RC, Meade S, et al
    Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel.
    Gut. 2020;69:1769-1777.
    PubMed     Abstract available


  20. STOURNARAS E, Qian W, Pappas A, Hong YY, et al
    Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource.
    Gut. 2020 Oct 1. pii: gutjnl-2019-320185. doi: 10.1136/gutjnl-2019-320185.
    PubMed     Abstract available


  21. JIJON H, Ueno A, Sharifi N, Leung Y, et al
    Elevated interferon-gamma levels during pregnancy are associated with adverse maternofetal outcomes in IBD.
    Gut. 2020;69:1895-1897.
    PubMed    


    September 2020
  22. BEELEN EMJ, van der Woude CJ, de Vries AC
    Intestinal resection rates in Crohn's disease decline across two different epidemiological areas: a consistent observation not merely due to introduction of anti-TNFalpha.
    Gut. 2020;69:1.
    PubMed    


  23. KHALILI H, Hakansson N, Chan SS, Chen Y, et al
    Adherence to a Mediterranean diet is associated with a lower risk of later-onset Crohn's disease: results from two large prospective cohort studies.
    Gut. 2020;69:1637-1644.
    PubMed     Abstract available


    August 2020
  24. EFFENBERGER M, Grabherr F, Mayr L, Schwaerzler J, et al
    Faecal calprotectin indicates intestinal inflammation in COVID-19.
    Gut. 2020;69:1543-1544.
    PubMed    


  25. SEYED TABIB NS, Madgwick M, Sudhakar P, Verstockt B, et al
    Big data in IBD: big progress for clinical practice.
    Gut. 2020;69:1520-1532.
    PubMed     Abstract available


    July 2020
  26. GOTTLIEB K, Daperno M, Usiskin K, Sands BE, et al
    Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developments.
    Gut. 2020 Jul 22. pii: gutjnl-2020-320690. doi: 10.1136/gutjnl-2020-320690.
    PubMed     Abstract available


  27. TURSI A, Angarano G, Monno L, Saracino A, et al
    COVID-19 infection in Crohn's disease under treatment with adalimumab.
    Gut. 2020;69:1364-1365.
    PubMed    


  28. BEZZIO C, Saibeni S, Variola A, Allocca M, et al
    Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study.
    Gut. 2020;69:1213-1217.
    PubMed     Abstract available


  29. NEURATH MF
    COVID-19 and immunomodulation in IBD.
    Gut. 2020;69:1335-1342.
    PubMed     Abstract available


  30. PAPAMICHAEL K, Cheifetz AS, Irving PM
    New role for azathioprine in case of switching anti-TNFs in IBD.
    Gut. 2020;69:1165-1167.
    PubMed    


  31. ZUO T, Ng SC
    Authors response: giant oversights in the human gut virome.
    Gut. 2020;69:1358.
    PubMed    


  32. SUTTON TDS, Clooney AG, Hill C
    Giant oversights in the human gut virome.
    Gut. 2020;69:1357-1358.
    PubMed    


  33. DANESE S, Schabel E, Ainsworth MA, Peyrin-Biroulet L, et al
    Challenges and opportunities for IBD drug development: from early stage to regulatory approval.
    Gut. 2020;69:1157-1161.
    PubMed    


  34. ROBLIN X, Williet N, Boschetti G, Phelip JM, et al
    Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial.
    Gut. 2020;69:1206-1212.
    PubMed     Abstract available


    June 2020
  35. ZHANG B, Wang HE, Bai YM, Tsai SJ, et al
    Inflammatory bowel disease is associated with higher dementia risk: a nationwide longitudinal study.
    Gut. 2020 Jun 23. pii: gutjnl-2020-320789. doi: 10.1136/gutjnl-2020-320789.
    PubMed     Abstract available


  36. BEZZIO C, Manes G, Bini F, Pellegrini L, et al
    Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds.
    Gut. 2020 Jun 17. pii: gutjnl-2020-321760. doi: 10.1136/gutjnl-2020-321760.
    PubMed    


  37. CLOONEY AG, Eckenberger J, Laserna-Mendieta E, Sexton KA, et al
    Ranking microbiome variance in inflammatory bowel disease: a large longitudinal intercontinental study.
    Gut. 2020 Jun 14. pii: gutjnl-2020-321106. doi: 10.1136/gutjnl-2020-321106.
    PubMed     Abstract available


  38. KOELINK PJ, Bloemendaal FM, Li B, Westera L, et al
    Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling.
    Gut. 2020;69:1053-1063.
    PubMed     Abstract available


    May 2020
  39. AXELRAD JE, Olen O, Sachs MC, Erichsen R, et al
    Inflammatory bowel disease and risk of small bowel cancer: a binational population-based cohort study from Denmark and Sweden.
    Gut. 2020 May 30. pii: gutjnl-2020-320945. doi: 10.1136/gutjnl-2020-320945.
    PubMed     Abstract available


  40. QI X, Liu Y, Wang J, Fallowfield J, et al
    Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study.
    Gut. 2020 May 20. pii: gutjnl-2020-321666. doi: 10.1136/gutjnl-2020-321666.
    PubMed    


  41. CLOUGH JN, Omer OS, Tasker S, Lord GM, et al
    Regulatory T-cell therapy in Crohn's disease: challenges and advances.
    Gut. 2020;69:942-952.
    PubMed     Abstract available


  42. KIRCHGESNER J, Nyboe Andersen N, Carrat F, Jess T, et al
    Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study.
    Gut. 2020;69:852-858.
    PubMed     Abstract available


  43. GARG M, Royce SG, Tikellis C, Shallue C, et al
    Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?
    Gut. 2020;69:841-851.
    PubMed     Abstract available


    April 2020
  44. KENNEDY NA, Jones GR, Lamb CA, Appleby R, et al
    British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic.
    Gut. 2020 Apr 17. pii: gutjnl-2020-321244. doi: 10.1136/gutjnl-2020-321244.
    PubMed     Abstract available


  45. MAZZA S, Sorce A, Peyvandi F, Vecchi M, et al
    A fatal case of COVID-19 pneumonia occurring in a patient with severe acute ulcerative colitis.
    Gut. 2020 Apr 3. pii: gutjnl-2020-321183. doi: 10.1136/gutjnl-2020-321183.
    PubMed    


  46. FAIRBRASS KM, Hoshen D, Gracie DJ, Ford AC, et al
    Effect of ACE inhibitors and angiotensin II receptor blockers on disease outcomes in inflammatory bowel disease.
    Gut. 2020 Apr 2. pii: gutjnl-2020-321186. doi: 10.1136/gutjnl-2020-321186.
    PubMed    


  47. PANACCIONE R, Colombel JF, Travis SPL, Bossuyt P, et al
    Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial.
    Gut. 2020;69:658-664.
    PubMed     Abstract available


  48. BOSSUYT P, Vermeire S, Bisschops R
    Scoring endoscopic disease activity in IBD: artificial intelligence sees more and better than we do.
    Gut. 2020;69:788-789.
    PubMed    


    March 2020
  49. VALLERAND I, Frolkis AD, Patten S, Kaplan GG, et al
    Changing trends in coding for depression among the UK IBD population: reply from authors.
    Gut. 2020;69:607.
    PubMed    


  50. POWELL N, Pantazi E, Pavlidis P, Tsakmaki A, et al
    Interleukin-22 orchestrates a pathological endoplasmic reticulum stress response transcriptional programme in colonic epithelial cells.
    Gut. 2020;69:578-590.
    PubMed     Abstract available


  51. VAN DER GIESSEN J, Binyamin D, Belogolovski A, Frishman S, et al
    Modulation of cytokine patterns and microbiome during pregnancy in IBD.
    Gut. 2020;69:473-486.
    PubMed     Abstract available


  52. SOKOL H, Brot L, Stefanescu C, Auzolle C, et al
    Prominence of ileal mucosa-associated microbiota to predict postoperative endoscopic recurrence in Crohn's disease.
    Gut. 2020;69:462-472.
    PubMed     Abstract available


  53. OLEN O, Askling J, Sachs MC, Neovius M, et al
    Mortality in adult-onset and elderly-onset IBD: a nationwide register-based cohort study 1964-2014.
    Gut. 2020;69:453-461.
    PubMed     Abstract available


    February 2020
  54. MURTHY SK, Begum J, Benchimol EI, Bernstein CN, et al
    Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study.
    Gut. 2020;69:274-282.
    PubMed     Abstract available


  55. SUN R, Hedl M, Abraham C
    IL23 group> IL23R recycling and amplifies innate receptor-induced signalling and cytokines in human macrophages, and the IBD-protective IL23R R381Q variant modulates these outcomes.
    Gut. 2020;69:264-273.
    PubMed     Abstract available


  56. SCHLEIER L, Wiendl M, Heidbreder K, Binder MT, et al
    Non-classical monocyte homing to the gut via alpha4beta7 integrin mediates macrophage-dependent intestinal wound healing.
    Gut. 2020;69:252-263.
    PubMed     Abstract available


    January 2020
  57. DOLMAN GE, Kennedy PTF
    Hepatitis B reactivation: reducing the risk in patients with inflammatory bowel disease.
    Gut. 2020 Jan 30. pii: gutjnl-2019-319480. doi: 10.1136/gutjnl-2019-319480.
    PubMed    


  58. BOSSUYT P, Nakase H, Vermeire S, de Hertogh G, et al
    Automatic, computer-aided determination of endoscopic and histological inflammation in patients with mild to moderate ulcerative colitis based on red density.
    Gut. 2020 Jan 8. pii: gutjnl-2019-320056. doi: 10.1136/gutjnl-2019-320056.
    PubMed     Abstract available


  59. NG SC, Kamm MA, Yeoh YK, Chan PKS, et al
    Scientific frontiers in faecal microbiota transplantation: joint document of Asia-Pacific Association of Gastroenterology (APAGE) and Asia-Pacific Society for Digestive Endoscopy (APSDE).
    Gut. 2020;69:83-91.
    PubMed     Abstract available


  60. TORRES J, Hu J, Seki A, Eisele C, et al
    Infants born to mothers with IBD present with altered gut microbiome that transfers abnormalities of the adaptive immune system to germ-free mice.
    Gut. 2020;69:42-51.
    PubMed     Abstract available


  61. TURNER D, Griffiths AM, Wilson D, Mould DR, et al
    Designing clinical trials in paediatric inflammatory bowel diseases: a PIBDnet commentary.
    Gut. 2020;69:32-41.
    PubMed     Abstract available


  62. WAN QY, Zhao R, Wu XT
    Older patients with IBD might have higher risk of Parkinson's disease.
    Gut. 2020;69:193-194.
    PubMed    


  63. TULKENS J, Vergauwen G, Van Deun J, Geeurickx E, et al
    Increased levels of systemic LPS-positive bacterial extracellular vesicles in patients with intestinal barrier dysfunction.
    Gut. 2020;69:191-193.
    PubMed    


    December 2019
  64. MAASER C, Petersen F, Helwig U, Fischer I, et al
    Intestinal ultrasound for monitoring therapeutic response in patients with ulcerative colitis: results from the TRUST&UC study.
    Gut. 2019 Dec 20. pii: gutjnl-2019-319451. doi: 10.1136/gutjnl-2019-319451.
    PubMed     Abstract available


  65. CHA JM, Park SH, Rhee KH, Hong SN, et al
    Long-term prognosis of ulcerative colitis and its temporal changes between 1986 and 2015 in a population-based cohort in the Songpa-Kangdong district of Seoul, Korea.
    Gut. 2019 Dec 10. pii: gutjnl-2019-319699. doi: 10.1136/gutjnl-2019-319699.
    PubMed     Abstract available


  66. DE BARRIOS O, Sanchez-Moral L, Cortes M, Ninfali C, et al
    ZEB1 promotes inflammation and progression towards inflammation-driven carcinoma through repression of the DNA repair glycosylase MPG in epithelial cells.
    Gut. 2019;68:2129-2141.
    PubMed     Abstract available


  67. LIMKETKAI BN, Shah SC, Hirano I, Bellaguarda E, et al
    Epidemiology and implications of concurrent diagnosis of eosinophilic oesophagitis and IBD based on a prospective population-based analysis.
    Gut. 2019;68:2152-2160.
    PubMed     Abstract available


    November 2019
  68. JONES GR, Lyons M, Plevris N, Jenkinson PW, et al
    IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology.
    Gut. 2019;68:1953-1960.
    PubMed     Abstract available


  69. ALLEZ M, Auzolle C, Ngollo M, Bottois H, et al
    T cell clonal expansions in ileal Crohn's disease are associated with smoking behaviour and postoperative recurrence.
    Gut. 2019;68:1961-1970.
    PubMed     Abstract available


  70. PAI RK, Khanna R, D'Haens GR, Sandborn WJ, et al
    Definitions of response and remission for the Robarts Histopathology Index.
    Gut. 2019;68:2101-2102.
    PubMed    


    October 2019
  71. DE GROOF EJ, Stevens TW, Eshuis EJ, Gardenbroek TJ, et al
    Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn's disease: the LIR!C Trial.
    Gut. 2019;68:1774-1780.
    PubMed     Abstract available


    September 2019
  72. LAMB CA, Kennedy NA, Raine T, Hendy PA, et al
    British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.
    Gut. 2019 Sep 27. pii: gutjnl-2019-318484. doi: 10.1136/gutjnl-2019-318484.
    PubMed     Abstract available


  73. VILLUMSEN M, Aznar S, Pakkenberg B, Brudek T, et al
    Authors' response: Association between IBD and Parkinson's disease: seek and you shall find?
    Gut. 2019;68:1722.
    PubMed    


  74. PARKES M
    IBD BioResource: an open-access platform of 25 000 patients to accelerate research in Crohn's and Colitis.
    Gut. 2019;68:1537-1540.
    PubMed    


    August 2019
  75. VERSTOCKT B, Verstockt S, Blevi H, Cleynen I, et al
    TREM-1, the ideal predictive biomarker for endoscopic healing in anti-TNF-treated Crohn's disease patients?
    Gut. 2019;68:1531-1533.
    PubMed    


  76. BIASCI D, Lee JC, Noor NM, Pombal DR, et al
    A blood-based prognostic biomarker in IBD.
    Gut. 2019;68:1386-1395.
    PubMed     Abstract available


    July 2019
  77. WALDSCHMITT N, Kitamoto S, Secher T, Zacharioudaki V, et al
    The regenerating family member 3 beta instigates IL-17A-mediated neutrophil recruitment downstream of NOD1/2 signalling for controlling colonisation resistance independently of microbiota community structure.
    Gut. 2019;68:1190-1199.
    PubMed     Abstract available


  78. TITO RY, Chaffron S, Caenepeel C, Lima-Mendez G, et al
    Population-level analysis of Blastocystis subtype prevalence and variation in the human gut microbiota.
    Gut. 2019;68:1180-1189.
    PubMed     Abstract available


    June 2019
  79. PETERSEN BS, Bokemeyer B, Wenker C, Hoby S, et al
    First known case of paediatric inflammatory bowel disease in a western lowland gorilla may be linked to a familial mutation in the MEFV gene.
    Gut. 2019 Jun 21. pii: gutjnl-2019-319051. doi: 10.1136/gutjnl-2019-319051.
    PubMed    


  80. DANESE S, Argollo M, Le Berre C, Peyrin-Biroulet L, et al
    JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?
    Gut. 2019 Jun 21. pii: gutjnl-2019-318448. doi: 10.1136/gutjnl-2019-318448.
    PubMed     Abstract available


  81. BETTENWORTH D, Bokemeyer A, Baker M, Mao R, et al
    Assessment of Crohn's disease-associated small bowel strictures and fibrosis on cross-sectional imaging: a systematic review.
    Gut. 2019;68:1115-1126.
    PubMed     Abstract available


    May 2019
  82. ZUNDLER S, Becker E, Schulze LL, Neurath MF, et al
    Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances.
    Gut. 2019 May 24. pii: gutjnl-2018-317977. doi: 10.1136/gutjnl-2018-317977.
    PubMed     Abstract available


  83. LYNGE E, Petersen MS, Lophaven SN
    Inflammatory bowel disease and Parkinson's disease.
    Gut. 2019 May 10. pii: gutjnl-2019-318958. doi: 10.1136/gutjnl-2019-318958.
    PubMed    


  84. BUTWICKA A, Sariaslan A, Larsson H, Halfvarson J, et al
    No association between urbanisation, neighbourhood deprivation and IBD: a population-based study of 4 million individuals.
    Gut. 2019;68:947-948.
    PubMed    


  85. MEDDENS CA, van der List ACJ, Nieuwenhuis EES, Mokry M, et al
    Non-coding DNA in IBD: from sequence variation in DNA regulatory elements to novel therapeutic potential.
    Gut. 2019;68:928-941.
    PubMed     Abstract available


  86. SCHMITT H, Billmeier U, Dieterich W, Rath T, et al
    Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease.
    Gut. 2019;68:814-828.
    PubMed     Abstract available


    April 2019
  87. LEMOINNE S, Kemgang A, Ben Belkacem K, Straube M, et al
    Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis.
    Gut. 2019 Apr 19. pii: gutjnl-2018-317791. doi: 10.1136/gutjnl-2018-317791.
    PubMed     Abstract available


  88. GAUJOUX R, Starosvetsky E, Maimon N, Vallania F, et al
    Cell-centred meta-analysis reveals baseline predictors of anti-TNFalpha non-response in biopsy and blood of patients with IBD.
    Gut. 2019;68:604-614.
    PubMed     Abstract available


  89. TOMINAGA K, Tsuchiya A, Yokoyama J, Terai S, et al
    How do you treat this diversion ileitis and pouchitis?
    Gut. 2019;68:593-758.
    PubMed    


  90. MAGRO F, Lopes J, Borralho P, Lopes S, et al
    Comparison of different histological indexes in the assessment of UC activity and their accuracy regarding endoscopic outcomes and faecal calprotectin levels.
    Gut. 2019;68:594-603.
    PubMed     Abstract available


    March 2019
  91. VAN DER POST S, Jabbar KS, Birchenough G, Arike L, et al
    Structural weakening of the colonic mucus barrier is an early event in ulcerative colitis pathogenesis.
    Gut. 2019 Mar 26. pii: gutjnl-2018-317571. doi: 10.1136/gutjnl-2018-317571.
    PubMed     Abstract available


  92. FROLKIS AD, Vallerand IA, Patten SB, Kaplan GG, et al
    Depression in inflammatory bowel disease: risk factor, prodrome or extraintestinal manifestation? Reply from authors.
    Gut. 2019 Mar 20. pii: gutjnl-2019-318650. doi: 10.1136/gutjnl-2019-318650.
    PubMed    


  93. ZUO T, Lu XJ, Zhang Y, Cheung CP, et al
    Gut mucosal virome alterations in ulcerative colitis.
    Gut. 2019 Mar 6. pii: gutjnl-2018-318131. doi: 10.1136/gutjnl-2018-318131.
    PubMed     Abstract available


    February 2019
  94. MOULTON CD, Norton C, Powell N, Mohamedali Z, et al
    Depression in inflammatory bowel disease: risk factor, prodrome or extraintestinal manifestation?
    Gut. 2019 Feb 26. pii: gutjnl-2019-318444. doi: 10.1136/gutjnl-2019-318444.
    PubMed    


  95. BLACKWELL J, Saxena S, Pollok RC
    Changing trends in coding for depression among the UK inflammatory bowel disease population.
    Gut. 2019 Feb 13. pii: gutjnl-2019-318296. doi: 10.1136/gutjnl-2019-318296.
    PubMed    


  96. HARPAZ N, Ballentine S, Colombel JF, E Sands B, et al
    Microscopic heterogeneity in ulcerative colitis: implications for microscopic measurement of disease activity.
    Gut. 2019 Feb 5. pii: gutjnl-2018-318137. doi: 10.1136/gutjnl-2018-318137.
    PubMed    


  97. SAHNAN K, Tozer PJ, Adegbola SO, Lee MJ, et al
    Developing a core outcome set for fistulising perianal Crohn's disease.
    Gut. 2019;68:226-238.
    PubMed     Abstract available


  98. LEVINE A, Kori M, Kierkus J, Sigall Boneh R, et al
    Azithromycin and metronidazole versus metronidazole-based therapy for the induction of remission in mild to moderate paediatric Crohn's disease : a randomised controlled trial.
    Gut. 2019;68:239-247.
    PubMed     Abstract available


    January 2019
  99. VIGOD SN, Kurdyak P, Brown HK, Nguyen GC, et al
    Inflammatory bowel disease and new-onset psychiatric disorders in pregnancy and post partum: a population-based cohort study.
    Gut. 2019 Jan 9. pii: gutjnl-2018-317610. doi: 10.1136/gutjnl-2018-317610.
    PubMed     Abstract available


  100. ROGLER G
    Mechanism of action of vedolizumab: do we really understand it?
    Gut. 2019;68:4-5.
    PubMed    


  101. HUTFLESS S, Wenning GK
    Which way does the axis tip? IBD increases the risk of Parkinson's disease.
    Gut. 2019;68:3.
    PubMed    


  102. GOUYNOU C, Pouillon L, Rousseau H, Zallot C, et al
    Early changes in the pharmacokinetic profile of vedolizumab-treated patients with IBD may predict response after dose optimisation.
    Gut. 2019;68:178-179.
    PubMed    


  103. DANESE S, Vermeire S, Hellstern P, Panaccione R, et al
    Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II).
    Gut. 2019;68:40-48.
    PubMed     Abstract available


    December 2018
  104. IACUCCI M, Furfaro F, Matsumoto T, Uraoka T, et al
    Advanced endoscopic techniques in the assessment of inflammatory bowel disease: new technology, new era.
    Gut. 2018 Dec 22. pii: gutjnl-2017-315235. doi: 10.1136/gutjnl-2017-315235.
    PubMed     Abstract available


  105. STJARNGRIM J, Ekbom A, Hammar U, Hultcrantz R, et al
    Rates and characteristics of postcolonoscopy colorectal cancer in the Swedish IBD population: what are the differences from a non-IBD population?
    Gut. 2018 Dec 15. pii: gutjnl-2018-316651. doi: 10.1136/gutjnl-2018-316651.
    PubMed     Abstract available


  106. BLACKWELL J, Saxena S, Pollok RC
    Role of thiopurines as disease-modifying agents in Crohn's disease.
    Gut. 2018;67:2229-2230.
    PubMed    


    November 2018
  107. UNGARO RC, Limketkai BN, Jensen CB, Allin KH, et al
    Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts.
    Gut. 2018 Nov 12. pii: gutjnl-2018-317021. doi: 10.1136/gutjnl-2018-317021.
    PubMed     Abstract available


    October 2018
  108. FROLKIS AD, Vallerand IA, Shaheen AA, Lowerison MW, et al
    Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression.
    Gut. 2018 Oct 18. pii: gutjnl-2018-317182. doi: 10.1136/gutjnl-2018-317182.
    PubMed     Abstract available


  109. HAMMOUDI N, Gardair C, Tran-Minh ML, Allez M, et al
    Rare cause of rectal stenosis in a patient with long-term use of Infliximab and Mercaptopurine for ulcerative colitis.
    Gut. 2018 Oct 9. pii: gutjnl-2018-317069. doi: 10.1136/gutjnl-2018-317069.
    PubMed     Abstract available


  110. XU P, Becker H, Elizalde M, Masclee A, et al
    Intestinal organoid culture model is a valuable system to study epithelial barrier function in IBD.
    Gut. 2018;67:1905-1906.
    PubMed    


  111. SANDBORN WJ, Lee SD, Tarabar D, Louis E, et al
    Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study.
    Gut. 2018;67:1824-1835.
    PubMed     Abstract available


  112. GERNER RR, Klepsch V, Macheiner S, Arnhard K, et al
    NAD metabolism fuels human and mouse intestinal inflammation.
    Gut. 2018;67:1813-1823.
    PubMed     Abstract available


    September 2018
  113. VAZQUEZ-BAEZA Y, Gonzalez A, Xu ZZ, Washburne A, et al
    Guiding longitudinal sampling in IBD cohorts.
    Gut. 2018;67:1743-1745.
    PubMed    


  114. LEVINE A, Sigall Boneh R, Wine E
    Evolving role of diet in the pathogenesis and treatment of inflammatory bowel diseases.
    Gut. 2018;67:1726-1738.
    PubMed     Abstract available


    August 2018
  115. TAN LZ, Reilly CR, Steward-Harrison LC, Balouch F, et al
    Oral vancomycin induces clinical and mucosal remission of colitis in children with primary sclerosing cholangitis-ulcerative colitis.
    Gut. 2018 Aug 21. pii: gutjnl-2018-316599. doi: 10.1136/gutjnl-2018-316599.
    PubMed    


  116. JAIRATH V, Peyrin-Biroulet L, Zou G, Mosli M, et al
    Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial.
    Gut. 2018 Aug 3. pii: gutjnl-2018-316702. doi: 10.1136/gutjnl-2018-316702.
    PubMed     Abstract available


  117. CONCEICAO-NETO N, Deboutte W, Dierckx T, Machiels K, et al
    Low eukaryotic viral richness is associated with faecal microbiota transplantation success in patients with UC.
    Gut. 2018;67:1558-1559.
    PubMed    


    July 2018
  118. POTTER MDE, Walker MM, Keely S, Talley NJ, et al
    What's in a name? 'Non-coeliac gluten or wheat sensitivity': controversies and mechanisms related to wheat and gluten causing gastrointestinal symptoms or disease.
    Gut. 2018 Jul 30. pii: gutjnl-2018-316360. doi: 10.1136/gutjnl-2018-316360.
    PubMed    


  119. MAO R, Chen Y, Xie X, Chen M, et al
    Gastrointestinal ultrasound in inflammatory bowel disease: experience from the Chinese IBD Elite Union.
    Gut. 2018 Jul 27. pii: gutjnl-2018-317070. doi: 10.1136/gutjnl-2018-317070.
    PubMed    


  120. WEIMERS P, Halfvarson J, Sachs MC, Ludvigsson JF, et al
    Association between inflammatory bowel disease and Parkinson's disease: seek and you shall find?
    Gut. 2018 Jul 18. pii: gutjnl-2018-316937. doi: 10.1136/gutjnl-2018-316937.
    PubMed    


  121. BAKER AM, Cross W, Curtius K, Al Bakir I, et al
    Evolutionary history of human colitis-associated colorectal cancer.
    Gut. 2018 Jul 10. pii: gutjnl-2018-316191. doi: 10.1136/gutjnl-2018-316191.
    PubMed     Abstract available


  122. KIRCHGESNER J, Beaugerie L, Carrat F, Andersen NN, et al
    Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study.
    Gut. 2018;67:1261-1268.
    PubMed     Abstract available


    June 2018
  123. KOTZE PG, Shen B, Lightner A, Yamamoto T, et al
    Modern management of perianal fistulas in Crohn's disease: future directions.
    Gut. 2018;67:1181-1194.
    PubMed     Abstract available


  124. BISSCHOPS R, Bessissow T, Joseph JA, Baert F, et al
    Chromoendoscopy versus narrow band imaging in UC: a prospective randomised controlled trial.
    Gut. 2018;67:1087-1094.
    PubMed     Abstract available


  125. ZHOU G, Yu L, Fang L, Yang W, et al
    CD177(+) neutrophils as functionally activated neutrophils negatively regulate IBD.
    Gut. 2018;67:1052-1063.
    PubMed     Abstract available


    May 2018
  126. VILLUMSEN M, Aznar S, Pakkenberg B, Jess T, et al
    Inflammatory bowel disease increases the risk of Parkinson's disease: a Danish nationwide cohort study 1977-2014.
    Gut. 2018 May 21. pii: gutjnl-2017-315666. doi: 10.1136/gutjnl-2017-315666.
    PubMed     Abstract available


  127. ZEISSIG S, Rosati E, Dowds CM, Aden K, et al
    Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.
    Gut. 2018 May 5. pii: gutjnl-2018-316023. doi: 10.1136/gutjnl-2018-316023.
    PubMed     Abstract available


  128. TEN HOVE JR, Shah SC, Shaffer SR, Bernstein CN, et al
    Consecutive negative findings on colonoscopy during surveillance predict a low risk of advanced neoplasia in patients with inflammatory bowel disease with long-standing colitis: results of a 15-year multicentre, multinational cohort study.
    Gut. 2018 May 2. pii: gutjnl-2017-315440. doi: 10.1136/gutjnl-2017-315440.
    PubMed     Abstract available


  129. VAN STAPPEN T, Vande Casteele N, Van Assche G, Ferrante M, et al
    Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial.
    Gut. 2018;67:818-826.
    PubMed     Abstract available


    April 2018
  130. ERIKSSON C, Rundquist S, Cao Y, Montgomery S, et al
    Impact of thiopurines on the natural history and surgical outcome of ulcerative colitis: a cohort study.
    Gut. 2018 Apr 4. pii: gutjnl-2017-315521. doi: 10.1136/gutjnl-2017-315521.
    PubMed     Abstract available


  131. MOUSSATA D, Allez M, Cazals-Hatem D, Treton X, et al
    Are random biopsies still useful for the detection of neoplasia in patients with IBD undergoing surveillance colonoscopy with chromoendoscopy?
    Gut. 2018;67:616-624.
    PubMed     Abstract available


    March 2018
  132. OKUGAWA Y, Toiyama Y, Kusunoki M, Goel A, et al
    Re: Cumulative burden of inflammation predicts colorectal neoplasia risk in ulcerative colitis: a large single-centre study.
    Gut. 2018 Mar 13. pii: gutjnl-2018-316205. doi: 10.1136/gutjnl-2018-316205.
    PubMed    


    February 2018
  133. BRYANT RV, Friedman A, Wright EK, Taylor K, et al
    Gastrointestinal ultrasound in inflammatory bowel disease: an underused resource with potential paradigm-changing application.
    Gut. 2018 Feb 3. pii: gutjnl-2017-315655. doi: 10.1136/gutjnl-2017-315655.
    PubMed     Abstract available


  134. LAHARIE D, Bourreille A, Branche J, Allez M, et al
    Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab.
    Gut. 2018;67:237-243.
    PubMed     Abstract available


  135. SIEGEL CA, Whitman CB, Spiegel BMR, Feagan B, et al
    Development of an index to define overall disease severity in IBD.
    Gut. 2018;67:244-254.
    PubMed     Abstract available


    January 2018
  136. ORTQVIST AK, Lundholm C, Halfvarson J, Ludvigsson JF, et al
    Fetal and early life antibiotics exposure and very early onset inflammatory bowel disease: a population-based study.
    Gut. 2018 Jan 10. pii: gutjnl-2017-314352. doi: 10.1136/gutjnl-2017-314352.
    PubMed     Abstract available


  137. BOUHNIK Y, Carbonnel F, Laharie D, Stefanescu C, et al
    Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study.
    Gut. 2018;67:53-60.
    PubMed     Abstract available


  138. ARIJS I, De Hertogh G, Lemmens B, Van Lommel L, et al
    Effect of vedolizumab (anti-alpha4beta7-integrin) therapy on histological healing and mucosal gene expression in patients with UC.
    Gut. 2018;67:43-52.
    PubMed     Abstract available


  139. WEISER M, Simon JM, Kochar B, Tovar A, et al
    Molecular classification of Crohn's disease reveals two clinically relevant subtypes.
    Gut. 2018;67:36-42.
    PubMed     Abstract available


  140. CARBALLAL S, Maisterra S, Lopez-Serrano A, Gimeno-Garcia AZ, et al
    Real-life chromoendoscopy for neoplasia detection and characterisation in long-standing IBD.
    Gut. 2018;67:70-78.
    PubMed     Abstract available


  141. BOUHNIK Y, Mary JY
    Adalimumab in Crohn's disease and symptomatic small bowel strictures.
    Gut. 2018;67:199.
    PubMed    


  142. SONAMBEKAR AA, Desai DC, Joshi A, Dhoble P, et al
    Adalimumab in Crohn's strictures--the CREOLE study.
    Gut. 2018;67:198.
    PubMed    


    December 2017
  143. DANESE S, Fiorino G, Peyrin-Biroulet L
    Early intervention in Crohn's disease: towards disease modification trials.
    Gut. 2017;66:2179-2187.
    PubMed     Abstract available


  144. COLOMBEL JF, Keir ME, Scherl A, Zhao R, et al
    Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC.
    Gut. 2017;66:2063-2068.
    PubMed     Abstract available


    November 2017
  145. CHOI CR, Al Bakir I, Ding NJ, Lee GH, et al
    Cumulative burden of inflammation predicts colorectal neoplasia risk in ulcerative colitis: a large single-centre study.
    Gut. 2017 Nov 17. pii: gutjnl-2017-314190. doi: 10.1136/gutjnl-2017-314190.
    PubMed     Abstract available


  146. PALMELA C, Chevarin C, Xu Z, Torres J, et al
    Adherent-invasive Escherichia coli in inflammatory bowel disease.
    Gut. 2017 Nov 15. pii: gutjnl-2017-314903. doi: 10.1136/gutjnl-2017-314903.
    PubMed     Abstract available


  147. KIM HS, Cheon JH, Jung ES, Park J, et al
    A coding variant in FTO confers susceptibility to thiopurine-induced leukopenia in East Asian patients with IBD.
    Gut. 2017;66:1926-1935.
    PubMed     Abstract available


  148. ZUNDLER S, Schillinger D, Fischer A, Atreya R, et al
    Blockade of alphaEbeta7 integrin suppresses accumulation of CD8+ and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo.
    Gut. 2017;66:1936-1948.
    PubMed     Abstract available


  149. ALLEZ M, Skolnick BE, Wisniewska-Jarosinska M, Petryka R, et al
    Anti-NKG2D monoclonal antibody (NNC0142-0002) in active Crohn's disease: a randomised controlled trial.
    Gut. 2017;66:1918-1925.
    PubMed     Abstract available


  150. HOCHART A, Gower-Rousseau C, Sarter H, Fumery M, et al
    Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study.
    Gut. 2017;66:1912-1917.
    PubMed     Abstract available


  151. HOVING JC, Cutler AJ, Leeto M, Horsnell WGC, et al
    Interleukin 13-mediated colitis in the absence of IL-4Ralpha signalling.
    Gut. 2017;66:2037-2039.
    PubMed    


    October 2017
  152. NORGARD BM, Magnussen B, Larsen MD, Friedman S, et al
    Reassuring results on birth outcomes in children fathered by men treated with azathioprine/6-mercaptopurine within 3 months before conception: a nationwide cohort study.
    Gut. 2017;66:1761-1766.
    PubMed     Abstract available


  153. JULSGAARD M, Kjeldsen J, Baumgart DC
    Vedolizumab safety in pregnancy and newborn outcomes.
    Gut. 2017;66:1866-1867.
    PubMed    


  154. SOMMER F, Ruhlemann MC, Bang C, Hoppner M, et al
    Microbiomarkers in inflammatory bowel diseases: caveats come with caviar.
    Gut. 2017;66:1734-1738.
    PubMed    


    September 2017
  155. BERTIN S, Aoki-Nonaka Y, Lee J, de Jong PR, et al
    The TRPA1 ion channel is expressed in CD4+ T cells and restrains T-cell-mediated colitis through inhibition of TRPV1.
    Gut. 2017;66:1584-1596.
    PubMed     Abstract available


  156. GURVITS GE
    When radiology meets gastroenterology: an unusual impact.
    Gut. 2017;66:1676.
    PubMed    


    August 2017
  157. PARIAN A, Limketkai B, Koh J, Brant SR, et al
    Appendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta-analysis.
    Gut. 2017;66:1390-1397.
    PubMed     Abstract available


  158. NYBOE ANDERSEN N, Gortz S, Frisch M, Jess T, et al
    Reduced risk of UC in families affected by appendicitis: a Danish national cohort study.
    Gut. 2017;66:1398-1402.
    PubMed     Abstract available


  159. O'BRIEN CL, Bringer MA, Holt KE, Gordon DM, et al
    Comparative genomics of Crohn's disease-associated adherent-invasive Escherichia coli.
    Gut. 2017;66:1382-1389.
    PubMed     Abstract available


    July 2017
  160. SPILLER RC, Sloan TJ
    Do diverticula provide a unique niche for microbiota which can lead to activation of the innate immune system?
    Gut. 2017;66:1175-1176.
    PubMed    


    June 2017
  161. PANES J, Sandborn WJ, Schreiber S, Sands BE, et al
    Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials.
    Gut. 2017;66:1049-1059.
    PubMed     Abstract available


  162. SCHWERD T, Pandey S, Yang HT, Bagola K, et al
    Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann-Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn's disease.
    Gut. 2017;66:1060-1073.
    PubMed     Abstract available


  163. SOKOL H, Leducq V, Aschard H, Pham HP, et al
    Fungal microbiota dysbiosis in IBD.
    Gut. 2017;66:1039-1048.
    PubMed     Abstract available


    May 2017
  164. PARANG B, Kaz AM, Barrett CW, Short SP, et al
    BVES regulates c-Myc stability via PP2A and suppresses colitis-induced tumourigenesis.
    Gut. 2017;66:852-862.
    PubMed     Abstract available


  165. PASCAL V, Pozuelo M, Borruel N, Casellas F, et al
    A microbial signature for Crohn's disease.
    Gut. 2017;66:813-822.
    PubMed     Abstract available


  166. LEE T, Clavel T, Smirnov K, Schmidt A, et al
    Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD.
    Gut. 2017;66:863-871.
    PubMed     Abstract available


  167. SCHEIBE K, Backert I, Wirtz S, Hueber A, et al
    IL-36R signalling activates intestinal epithelial cells and fibroblasts and promotes mucosal healing in vivo.
    Gut. 2017;66:823-838.
    PubMed     Abstract available


    April 2017
  168. LORD AR, Simms LA, Hanigan K, Sullivan R, et al
    Protective effects of Helicobacter pylori for IBD are related to the cagA-positive strain.
    Gut. 2017 Apr 13. pii: gutjnl-2017-313805. doi: 10.1136/gutjnl-2017-313805.
    PubMed    


  169. LIN W, Ma C, Su F, Jiang Y, et al
    Raf kinase inhibitor protein mediates intestinal epithelial cell apoptosis and promotes IBDs in humans and mice.
    Gut. 2017;66:597-610.
    PubMed     Abstract available


    March 2017
  170. FRIEDMAN S, Larsen PV, Fedder J, Norgard BM, et al
    The reduced chance of a live birth in women with IBD receiving assisted reproduction is due to a failure to achieve a clinical pregnancy.
    Gut. 2017;66:556-558.
    PubMed    


    February 2017
  171. NOBEN M, Verstockt B, de Bruyn M, Hendriks N, et al
    Epithelial organoid cultures from patients with ulcerative colitis and Crohn's disease: a truly long-term model to study the molecular basis for inflammatory bowel disease?
    Gut. 2017 Feb 3. pii: gutjnl-2016-313667. doi: 10.1136/gutjnl-2016-313667.
    PubMed    


  172. SUBRAMANIAN S, Ekbom A, Rhodes JM
    Recent advances in clinical practice: a systematic review of isolated colonic Crohn's disease: the third IBD?
    Gut. 2017;66:362-381.
    PubMed     Abstract available


  173. CASTANO-RODRIGUEZ N, Kaakoush NO, Lee WS, Mitchell HM, et al
    Dual role of Helicobacter and Campylobacter species in IBD: a systematic review and meta-analysis.
    Gut. 2017;66:235-249.
    PubMed     Abstract available


  174. QURAISHI MN, Sergeant M, Kay G, Iqbal T, et al
    The gut-adherent microbiota of PSC-IBD is distinct to that of IBD.
    Gut. 2017;66:386-388.
    PubMed    


    January 2017
  175. MOSLI MH, Feagan BG, Zou G, Sandborn WJ, et al
    Development and validation of a histological index for UC.
    Gut. 2017;66:50-58.
    PubMed     Abstract available


  176. MARCHAL-BRESSENOT A, Salleron J, Boulagnon-Rombi C, Bastien C, et al
    Development and validation of the Nancy histological index for UC.
    Gut. 2017;66:43-49.
    PubMed     Abstract available


  177. MACHIELS K, Sabino J, Vandermosten L, Joossens M, et al
    Specific members of the predominant gut microbiota predict pouchitis following colectomy and IPAA in UC.
    Gut. 2017;66:79-88.
    PubMed     Abstract available


  178. ATREYA I, Neurath MF
    Microbiota: relevant player in thiopurine metabolisation?
    Gut. 2017;66:1-3.
    PubMed    


  179. DONG R, Zheng S, Chen G
    The appropriate dose and cost of iron replacement therapy in patients with IBD.
    Gut. 2017;66:196-197.
    PubMed    


  180. GUINET-CHARPENTIER C, Lepage P, Morali A, Chamaillard M, et al
    Effects of enteral polymeric diet on gut microbiota in children with Crohn's disease.
    Gut. 2017;66:194-195.
    PubMed    


    November 2016
  181. OLIVERA P, Danese S, Peyrin-Biroulet L
    Next generation of small molecules in inflammatory bowel disease.
    Gut. 2016 Nov 17. pii: gutjnl-2016-312912. doi: 10.1136/gutjnl-2016-312912.
    PubMed    


  182. TEICH N, Bokemeyer B, Mohl W, Walldorf J, et al
    Blood group B is associated with azathioprine-induced acute pancreatitis in patients with IBD.
    Gut. 2016 Nov 14. pii: gutjnl-2016-313138. doi: 10.1136/gutjnl-2016-313138.
    PubMed    


  183. DOTTI I, Mora-Buch R, Ferrer-Picon E, Planell N, et al
    Alterations in the epithelial stem cell compartment could contribute to permanent changes in the mucosa of patients with ulcerative colitis.
    Gut. 2016 Nov 1. pii: gutjnl-2016-312609. doi: 10.1136/gutjnl-2016-312609.
    PubMed     Abstract available


    October 2016
  184. IMHANN F, Vich Vila A, Bonder MJ, Fu J, et al
    Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease.
    Gut. 2016 Oct 8. pii: gutjnl-2016-312135. doi: 10.1136/gutjnl-2016-312135.
    PubMed     Abstract available


    September 2016
  185. HASLER R, Sheibani-Tezerji R, Sinha A, Barann M, et al
    Uncoupling of mucosal gene regulation, mRNA splicing and adherent microbiota signatures in inflammatory bowel disease.
    Gut. 2016 Sep 30. pii: gutjnl-2016-311651. doi: 10.1136/gutjnl-2016-311651.
    PubMed     Abstract available


    July 2016
  186. JENDREK ST, Gotthardt D, Nitzsche T, Widmann L, et al
    Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis.
    Gut. 2016 Jul 12. pii: gutjnl-2016-311739. doi: 10.1136/gutjnl-2016-311739.
    PubMed     Abstract available


    May 2016
  187. SABINO J, Vieira-Silva S, Machiels K, Joossens M, et al
    Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD.
    Gut. 2016 May 20. pii: gutjnl-2015-311004. doi: 10.1136/gutjnl-2015-311004.
    PubMed     Abstract available


    June 2015
  188. HART PA, Levy MJ, Smyrk TC, Takahashi N, et al
    Clinical profiles and outcomes in idiopathic duct-centric chronic pancreatitis (type 2 autoimmune pancreatitis): the Mayo Clinic experience.
    Gut. 2015 Jun 17. pii: gutjnl-2015-309275. doi: 10.1136/gutjnl-2015-309275.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: